IL142479A0 - Esters of (+)-alpha-(2,3-dimethoxyphenyl) -1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol and their use as prodrugs of the 5ht2a receptor antagonist mdl 110,907 - Google Patents
Esters of (+)-alpha-(2,3-dimethoxyphenyl) -1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol and their use as prodrugs of the 5ht2a receptor antagonist mdl 110,907Info
- Publication number
- IL142479A0 IL142479A0 IL14247998A IL14247998A IL142479A0 IL 142479 A0 IL142479 A0 IL 142479A0 IL 14247998 A IL14247998 A IL 14247998A IL 14247998 A IL14247998 A IL 14247998A IL 142479 A0 IL142479 A0 IL 142479A0
- Authority
- IL
- Israel
- Prior art keywords
- piperidinemethanol
- dimethoxyphenyl
- prodrugs
- fluorophenyl
- alpha
- Prior art date
Links
- 150000002148 esters Chemical class 0.000 title 1
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
- 239000002400 serotonin 2A antagonist Substances 0.000 title 1
- HXTGXYRHXAGCFP-UHFFFAOYSA-N volinanserin Chemical compound COC1=CC=CC(C(O)C2CCN(CCC=3C=CC(F)=CC=3)CC2)=C1OC HXTGXYRHXAGCFP-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US1998/021608 WO2000021930A1 (en) | 1998-10-14 | 1998-10-14 | Esters of (+)-alpha-( 2,3- dimethoxyphenyl) -1-[2-(4- fluorophenyl) ethyl]-4- piperidinemethanol and their use as prodrugs of the 5ht2a receptor antagonist mdl 110,907 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL142479A0 true IL142479A0 (en) | 2002-03-10 |
Family
ID=22268079
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL14247998A IL142479A0 (en) | 1998-10-14 | 1998-10-14 | Esters of (+)-alpha-(2,3-dimethoxyphenyl) -1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol and their use as prodrugs of the 5ht2a receptor antagonist mdl 110,907 |
| IL142479A IL142479A (en) | 1998-10-14 | 2001-04-05 | Esters of (+) - alpha - (2,3 - dimethoxyphenyl)-1-[2-(4- fluorophenyl) ethyl]-4-piperidinemethanol, process for their preparation, pharmaceutical compositions containing them,and uses thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL142479A IL142479A (en) | 1998-10-14 | 2001-04-05 | Esters of (+) - alpha - (2,3 - dimethoxyphenyl)-1-[2-(4- fluorophenyl) ethyl]-4-piperidinemethanol, process for their preparation, pharmaceutical compositions containing them,and uses thereof |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1121345A1 (en) |
| JP (1) | JP2002527422A (en) |
| KR (1) | KR100515429B1 (en) |
| CN (1) | CN1160333C (en) |
| AU (1) | AU1083099A (en) |
| BR (1) | BR9816049A (en) |
| CA (1) | CA2347469C (en) |
| CZ (1) | CZ20011331A3 (en) |
| EA (1) | EA003667B1 (en) |
| EE (1) | EE200100219A (en) |
| HR (1) | HRP20010278A2 (en) |
| HU (1) | HUP0200517A3 (en) |
| IL (2) | IL142479A0 (en) |
| NO (1) | NO320417B1 (en) |
| NZ (1) | NZ510631A (en) |
| PL (1) | PL193306B1 (en) |
| SK (1) | SK5082001A3 (en) |
| TR (1) | TR200101047T2 (en) |
| UA (1) | UA57859C2 (en) |
| WO (1) | WO2000021930A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020099076A1 (en) * | 2000-05-25 | 2002-07-25 | Richard Scheyer D. | Use of (+)-a-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol or its prodrug in the treatment of symptoms of dementia and dopamine induced psychosis |
| CN102241667B (en) * | 2010-05-14 | 2013-10-23 | 中国人民解放军军事医学科学院毒物药物研究所 | 1-[(4-hydroxypiperidine-4-yl) methyl] pyridine-2(1H)-one derivatives, preparation method and use thereof |
| CN106892897A (en) * | 2015-12-21 | 2017-06-27 | 上海科胜药物研发有限公司 | A kind of hydroxyl piperazine pyrrone free alkali novel crystal forms and preparation method thereof |
| CN106928187A (en) * | 2015-12-31 | 2017-07-07 | 上海奥博生物医药技术有限公司 | A kind of hydrochloric acid hydroxyl piperazine pyrrone novel crystal forms and preparation method thereof |
| US20220273628A1 (en) * | 2021-02-19 | 2022-09-01 | Universitätsspital Basel | Effects of lysergic acid diethylamide (lsd) and of lsd analogs to assist psychotherapy for generalized anxiety disorder or other anxiety not related to life-threatening illness |
| CN117355302A (en) | 2021-04-30 | 2024-01-05 | 思维医学股份有限公司 | LSD salt crystal form |
| AU2022331315B2 (en) | 2021-08-19 | 2025-10-16 | Definium Therapeutics US, Inc. | Lyophilized orally disintegrating tablet formulations of d-lysergic acid diethylamide for therapeutic applications |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69105501T2 (en) * | 1990-06-01 | 1995-04-13 | Merrell Dow Pharma | (+) - ALPHA- (2,3 DIMETHOXYPHENYL) -1- [2- (FLUOROPHENYL) ETHYL] -4-PIPERIDINE METHANOL. |
-
1998
- 1998-10-14 CA CA002347469A patent/CA2347469C/en not_active Expired - Fee Related
- 1998-10-14 HU HU0200517A patent/HUP0200517A3/en unknown
- 1998-10-14 HR HR20010278A patent/HRP20010278A2/en not_active Application Discontinuation
- 1998-10-14 CZ CZ20011331A patent/CZ20011331A3/en unknown
- 1998-10-14 BR BR9816049-4A patent/BR9816049A/en not_active Application Discontinuation
- 1998-10-14 EE EEP200100219A patent/EE200100219A/en unknown
- 1998-10-14 EA EA200100361A patent/EA003667B1/en not_active IP Right Cessation
- 1998-10-14 JP JP2000575839A patent/JP2002527422A/en active Pending
- 1998-10-14 EP EP98953458A patent/EP1121345A1/en not_active Withdrawn
- 1998-10-14 TR TR2001/01047T patent/TR200101047T2/en unknown
- 1998-10-14 UA UA2001042522A patent/UA57859C2/en unknown
- 1998-10-14 SK SK508-2001A patent/SK5082001A3/en not_active Application Discontinuation
- 1998-10-14 IL IL14247998A patent/IL142479A0/en active IP Right Grant
- 1998-10-14 AU AU10830/99A patent/AU1083099A/en not_active Abandoned
- 1998-10-14 KR KR10-2001-7004703A patent/KR100515429B1/en not_active Expired - Fee Related
- 1998-10-14 CN CNB988142740A patent/CN1160333C/en not_active Expired - Fee Related
- 1998-10-14 PL PL347318A patent/PL193306B1/en not_active IP Right Cessation
- 1998-10-14 NZ NZ510631A patent/NZ510631A/en active IP Right Revival
- 1998-10-14 WO PCT/US1998/021608 patent/WO2000021930A1/en not_active Ceased
-
2001
- 2001-04-05 IL IL142479A patent/IL142479A/en not_active IP Right Cessation
- 2001-04-09 NO NO20011805A patent/NO320417B1/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| IL142479A (en) | 2006-06-11 |
| NO320417B1 (en) | 2005-12-05 |
| HRP20010278A2 (en) | 2002-06-30 |
| EA200100361A1 (en) | 2001-10-22 |
| HUP0200517A2 (en) | 2002-06-29 |
| EA003667B1 (en) | 2003-08-28 |
| NO20011805D0 (en) | 2001-04-09 |
| CA2347469C (en) | 2006-02-28 |
| PL347318A1 (en) | 2002-03-25 |
| HK1039332A1 (en) | 2002-04-19 |
| KR100515429B1 (en) | 2005-09-20 |
| TR200101047T2 (en) | 2001-08-21 |
| CZ20011331A3 (en) | 2001-08-15 |
| NO20011805L (en) | 2001-06-08 |
| EE200100219A (en) | 2002-08-15 |
| NZ510631A (en) | 2003-07-25 |
| AU1083099A (en) | 2000-05-01 |
| CN1160333C (en) | 2004-08-04 |
| PL193306B1 (en) | 2007-01-31 |
| JP2002527422A (en) | 2002-08-27 |
| UA57859C2 (en) | 2003-07-15 |
| SK5082001A3 (en) | 2001-11-06 |
| KR20010106517A (en) | 2001-11-29 |
| HUP0200517A3 (en) | 2002-12-28 |
| CA2347469A1 (en) | 2000-04-20 |
| BR9816049A (en) | 2001-07-03 |
| EP1121345A1 (en) | 2001-08-08 |
| WO2000021930A1 (en) | 2000-04-20 |
| CN1314887A (en) | 2001-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EG24533A (en) | Piperdine derivatives useful as CCR 5 antagonists | |
| HUP0101275A3 (en) | Amide derivatives and pharmaceutical compositions containing them as nociceptin antagonists | |
| HUP9603298A3 (en) | Heterocyclic compounds having tachykinin receptor antagonist activity, their preparation, and their use for the preparation of pharmaceutical compositions | |
| HRP980163B1 (en) | Pharmaceutical composition for the oral administration of an n-piperidinopyrazole -3-carboxamide derivative, its salts and their solvates | |
| HUP9701281A2 (en) | Piperidine derivatives as neurokinin antagonists and pharmaceutical compositions containing them | |
| HUP9900299A3 (en) | Paroxetine controlled release compositions | |
| AU5274499A (en) | Therapeutic chemokine receptor antagonists | |
| HUP0101688A3 (en) | Heterocyclically substituted amides and their use for producing pharmaceutical compositions | |
| HUP0400349A3 (en) | Ccr5 antagonists useful for treating aids and pharmaceutical compositions containing them | |
| AU5326100A (en) | Pharmaceutical compositions and methods for use | |
| AU5565099A (en) | Pharmaceutical compositions and methods for use | |
| AUPP968699A0 (en) | Therapeutic compositions and method for their preparation | |
| PL352432A1 (en) | Neurothrophic pyrolydines and piperidines, their affinite composition and methods of using them | |
| HUP0004648A3 (en) | 3-substituted tetrahydropyridopyrimidinone derivatives and their use for producing pharmaceutical compositions | |
| IL142479A0 (en) | Esters of (+)-alpha-(2,3-dimethoxyphenyl) -1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol and their use as prodrugs of the 5ht2a receptor antagonist mdl 110,907 | |
| IL127518A (en) | Substituted heterocyclic benzocycloalkenes, their preparation and pharmaceutical compositions having an analgesic effect | |
| PL333079A1 (en) | Piparazinic derivatives as antagonists of neurokinin | |
| IL126022A (en) | Use of (+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol in the preparation of pharmaceutical composition for treating depressive disorders and bipolar disorders | |
| IL152908A0 (en) | USE OF (+)-a- (2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL) ETHYL] -4-PIPERIDINEMETHANOL OR ITS PRODRUG IN THE TREATMENT OF SYMPTOMS OF DEMENTIA AND DOPAMINE INDUCED PSYCHOSIS | |
| HUP0004900A3 (en) | Pharmaceutical compositions for treating disease-related or drug-induced dyskinesias containing piperidine derivatives as nmda receptor antagonist as active ingredient | |
| HUP0400889A3 (en) | Processes for the preparation of (r)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol and pharmaceutical compositions containing the compound | |
| AU1573100A (en) | Composition of paroxetine methanesulfonate | |
| AU2673201A (en) | Alpha-arylethylpiperazine derivatives as neurokinin antagonists | |
| AU3611099A (en) | Oxindole derivatives used as neurokinin receptor antagonists | |
| HUP0101326A3 (en) | Paroxetine compositions and process for their preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed |